Ace inhibitor

Researchers at Columbia University Medical Center ( CUMC ) have discovered that the fusion of two adjacent genes can...


Chromosomal translocations that generate in-frame oncogenic gene fusions are notable examples of the success of targeted cancer therapies. Gene fusions...


The results from the one-year phase 3 CHRONOS study have shown that patients receiving the investigational drug Dupilumab ( Dupixent...



Findings from a real-world data analysis of the U.S. Medicare database comparing the risk of stroke or systemic embolism and...


Evolocumab ( Repatha ), a PCSK9 inhibitor, has shown to dramatically lower levels of low-density lipoprotein ( LDL), and also...


The FDA ( U.S. Food and Drug Administration ) has approved Xadago ( Safinamide ) tablets as an add-on treatment...


Researchers at the University of Texas MD Anderson Cancer Center in Houston, have found a link between microbes in the...


Ten years ago, the Adenoma Prevention With Celecoxib ( APC ) trial showed that the selective cyclooxygenase-2 ( COX-2 )...


Relapse is the major cause of failure after allogeneic stem cell transplantation ( Allo-SCT ) for acute myelogenous leukemia (...


The European Commission ( EC ) has granted marketing authorization for Stivarga ( Regorafenib ) for the treatment of adult...


The new drug LCZ696 is a treatment for chronic heart failure. LCZ696 is better than conventional drugs at reducing cardiac...


Phase 2 results for Ralinepag, an investigational, long-acting, orally administered prostacyclin receptor agonist under development for the treatment of...


Bristol-Myers Squibb pioneered the use of immune checkpoint inhibitors for the adjuvant treatment of melanoma, beginning with Yervoy. Five-year overall...


Results from the phase 3 SELECT-BEYOND clinical trial evaluating Upadacitinib ( ABT-494 ), an investigational oral JAK1-selective inhibitor, in patients...


Results from the phase 3 SELECT-MONOTHERAPY clinical trial were announced. This ongoing study evaluated Upadacitinib ( ABT-494 ), an investigational...


The phase 3 GLAGOV ( GLobal Assessment of Plaque ReGression with a PCSK9 AntibOdy as Measured by IntraVascular Ultrasound )...


In a phase III, double-blind 24-week study, RA-BUILD, 684 biologic disease-modifying antirheumatic drug (DMARD)-naïve patients with rheumatoid arthritis and...


Verubecestat is an investigational small molecule inhibitor of the enzyme beta-site amyloid precursor protein cleaving enzyme 1 ( BACE1 )...


New data showing Secukinumab ( Cosentyx ) delivers sustained improvements in the signs and symptoms of psoriatic arthritis over three...